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Background: Neuroblastoma (NB) is an aggressive childhood malignancy in children up to 5 years of age. High-stage
tumors frequently relapse even after aggressive multimodal treatment, and then show therapy resistance, typically
resulting in patient death. New molecular-targeted compounds that effectively suppress tumor growth and prevent
relapse with more efficacy are urgently needed. We and others previously showed that polyamines (PA) like spermidine
and spermine are essential for NB tumorigenesis and that DFMO, an inhibitor of the key PA synthesis gene product
ODC, is effective both in vitro and in vivo, securing its evaluation in NB clinical trials. To find additional compounds
interfering with PA biosynthesis, we tested sulfasalazine (SSZ), an FDA-approved salicylate-based anti-inflammatory and
immune-modulatory drug, recently identified to inhibit sepiapterin reductase (SPR). We earlier presented evidence for a
physical interaction between ODC and SPR and we showed that RNAi-mediated knockdown of SPR expression significantly
reduced native ODC enzyme activity and impeded NB cell proliferation.
Methods: Human NB mRNA expression datasets in the public domain were analyzed using the R2 platform. Cell viability,
isobologram, and combination index analyses as a result of SSZ treatment with our without DFMO were carried out in NB
cell cultures. Molecular protein-ligand docking was achieved using the GRAMM algorithm. Statistical analyses were
performed with the Kruskal-Wallis test, 2log Pearson test, and Student’s t test.
Results: In this study, we show the clinical relevance of SPR in human NB tumors. We found that high SPR expression is
significantly correlated to unfavorable NB characteristics like high age at diagnosis, MYCN amplification, and high INSS stage.
SSZ inhibits the growth of NB cells in vitro, presumably due to the inhibition of SPR as predicted by computational docking
of SSZ into SPR. Importantly, the combination of SSZ with DFMO produces synergistic antiproliferative effects in vitro.
Conclusions: The results suggest the use of SSZ in combination with DFMO for further experiments, and possible
prioritization as a novel therapy for the treatment of NB patients.
Keywords: Drug synergism DFMO, Molecular docking, Neuroblastoma, SPR, SulfasalazineBackground
Neuroblastoma (NB) is a childhood cancer that mainly af-
fects children up to 5 years of age [1–6]. NB is risk-
stratified according to patient age at diagnosis, disease
stage (INSS stages 1–4 and 4 s), and common genetic aber-
rations like MYCN oncogene amplification. This NB* Correspondence: andre.bachmann@hc.msu.edu
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creativecommons.org/publicdomain/zero/1.0/classification is used to determine the treatment regimen,
and is effective in predicting patient survival. Survival rates
range from > 90 % for low- to < 50 % for high-risk NB [7–
10]. Patients that suffer from high-risk NB, especially those
with tumor MYCN gene amplification, show incomplete
response to aggressive, multimodal therapy and often re-
lapse and ultimately die [1–6]. While considerable progress
in survival was attained by optimizing conventional inter-
ventions like chemotherapy, radiation, and bone marrow
transplantation, it is now widely accepted that a thera-
peutic plateau has been reached. Increased treatment in-
tensification is not considered likely to improve patientle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Sulfasalazine (SSZ)
Fig. 1 Structure of Sulfasalazine (SSZ). SSZ is an amino-salicylate, specifically
5-((4- (2- Pyridylsulfamoyl) phenyl)azo) salicylic acid (systemic name:
2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic
acid), with a molecular mass of 398.394 g/mol. SSZ was developed in
the 1950’s to treat rheumatoid arthritis and is also indicated for the use
in ulcerative cholitis and Crohn’s disease. SSZ is commercially distributed
under the brand names Azulfidine, Salazopyrin and Sulazine
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of the grave treatment complications by fine-tuning risk-
adapted therapy, and the development of more effectual,
more specific, and less harmful molecular targeted drugs
are currently viewed as the most important policies.
We and others have studied the polyamine (PA) bio-
synthetic pathway and its enzymes as novel targets in
NB. High PA levels increase tumor cell proliferation and
survival in NB and many other cancer types [13–17].
For NB, we have published that PA depletion upon
addition of alpha-difluoromethylornitine (DFMO), which
inhibits the key PA biosynthesis enzyme ornithine decarb-
oxylase (ODC), readily decreases cell proliferation by acti-
vating the p27Kip1/retinoblastoma (Rb) signaling axis and
by inducing cell cycle arrest in the G1 phase [18, 19].
We also showed that S-adenosylmethionine decarboxyl-
ase (AdoMetDC, also known as SAMDC or AMD) is
important for PA production in NB [20] and that PAs
contribute to NB cell migration and metastasis [21]. In
addition, we assessed the role of deoxyhypusine synthase
(DHPS) that uses spermidine as a substrate for post-
translational activation/hypusination of eukaryotic initi-
ation factor 5A (eIF5A), and found that its inhibition by
N1-guanyl-1,7-diaminoheptane (GC7) had a p21Cip1/Rb-
mediated negative effect on NB cell proliferation [22].
Importantly, DFMO was also effective in vivo in both
human NB tumor cell xenografts in mice and the trans-
genic TH-MYCN NB mouse model [23–25]. Considering
its excellent safety profile and its successful use in human
patients in combating trypanosomiasis (or African sleep-
ing sickness disease), we re-targeted DFMO for NB treat-
ment, advancing the drug through the Neuroblastoma
and Medulloblastoma Translational Research Consortium
(NMTRC) into multicenter phase I [26] and phase II (on-
going) clinical studies [27, 28].
We have previously shown that the combination of
DFMO with PA uptake inhibitor AMXT-1501 was syn-
ergistic in vitro [29]. In an attempt to find additional
compounds interfering with the PA biosynthesis pathway,
we tested sulfasalazine (SSZ), a well-documented, FDA-
approved salicylate-based anti-inflammatory and immune-
modulatory drug (Fig. 1). SSZ is used to treat bowel
inflammation in patients with ulcerative colitis and
Crohn’s disease and also indicated for use in rheuma-
toid arthritis. SSZ has recently been identified to inhibit
sepiapterin reductase (SPR), an important enzyme in the
biosynthesis of tetrahydrobiopterin (BH4) [30, 31]. BH4 is
an essential cofactor in the production of serotonin, dopa-
mine, epinephrine, norepinephrine, and nitric oxide syn-
thase (NOS).
We earlier presented evidence for a physical inter-
action between ODC and SPR and we showed that
RNAi-mediated knockdown of SPR expression signifi-
cantly reduced native ODC enzyme activity and impededthe proliferation of NB cells, demonstrating the biological
relevance of this novel interaction [32]. This current study
is the first report on the cellular effects of SSZ on NB
tumor cells, presumably due to the inhibition of SPR as
predicted by computational docking of SSZ into SPR. We
further demonstrate the clinical relevance of SPR in hu-
man NB tumors and show that the combination of SSZ
with DFMO produces synergistic antiproliferative effects,
suggesting the use of SSZ/DFMO combination therapies
in NB patients.Results
SPR mRNA expression in NB
We have previously reported on the role of SPR in NB
proliferation [32], where we demonstrated a deleterious
effect of RNAi-mediated SPR expression knockdown in
the MYCN2 NB cell line. We also showed that high SPR
mRNA expression was correlated to poor patient prog-
nosis in Kaplan-Meier analysis in the Versteeg-88 NB
dataset in the public domain. We now present SPR
mRNA expression analysis on all 12 NB cohorts in the
public domain (Table 1). We find that high SPR expres-
sion is significantly correlated in all four NB cohorts an-
notated for patient survival and/or prognosis. While in
our previous study [32] we could only show a trend for
a correlation between SPR expression and tumor MYCN
gene amplification in the Versteeg-88 set (P = 0.06), we
can now state that SPR expression is significantly higher
in patients with tumor MYCN gene amplification in 6 of
8 datasets with MYCN amplification annotation. Consid-
ering the different compositions of these datasets with
Table 1 SPR mRNA correlations in public NB mRNA expression
datasets
Dataset SPR mRNA expression
correlations
Micro-array data
Name Samples Survival/
prognosis
MYCN
amplification
Array Type GSE
Delattre 64 n.d. positive
(6.8 • 10-6)
Affymetrix
HG-U133
Plus 2.0
12460
Hiyama 51 negative
(0.02)
positive
(2.8 • 10-3)
Affymetrix
HG-U133
Plus 2.0
16237
Jagannathan 100 negative
(0.02)
positive
(1.7 • 10-3)
Illumina
Human
WG 6V2
19274
Kocak 649 n.d. positive
(7.9 • 10-15)
Agilent
Human
44K Oligo
45547
Łastowska 30 n.d. positive
(2.6 • 10-4)
Affymetrix
HG-U133
Plus 2.0
13136
Maris 101 n.d. n.s. Affymetrix
HG-U95A
3960
Seeger 117 negative
(1.4 • 10-4)
n.d. Affymetrix
HG-U133A
3446
Versteeg 88 negative
(0.02)
n.s. Affymetrix
HG-U133
Plus 2.0
16476
Zhang 498 negative (2.1
• 10-6)
positive
(4.6 • 10-4)
Agilent
Human
44K Oligo
49710
Legend: The Albino-28 (GSE7529), Khan-47 (GSE27608), and Seeger-102 (GSE3446)
do not contain sufficient clinical data and were not analyzed. Data were analyzed as
described in the Materials and Methods. The first two columns represent name and
sample size of the dataset. The two central columns show the results of SPR mRNA
expression correlation analyses: with survival and/or prognosis, and with MYCN
amplification. Negative or positive in the two central columns means that
SPR mRNA expression correlates negative or positive with survival/good
prognosis and MYCN amplification, respectively (outcomes of Kruskal-Wallis
correlation tests, the number in parentheses is the P value, n.s. means not
significant, n.d. means not determined (data not present in the dataset)).
Kocak-649 and Zhang-498 contain some common samples. The last two
columns list Array type and GEO GSE number on the NCBI GEO website
where full data are available
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stage, together with the different array platforms used for
the generation of these data, this is a very robust finding. In
Fig. 2, we show the results for the largest NB cohort in the
public domain, the Kocak-649 dataset. Although this data-
set does not contain survival data, the correlations between
SPR expression and three important clinical NB parameters
are highly significant (Fig. 2, a-c): age at diagnosis (P = 1.9 ·
10−23, MYCN tumor amplification (P = 7.9 · 10−15, and INSS
stage (various P values < 0.05). In addition, the Kocak-649
dataset shows a significant correlation between SPR and
ODC mRNA expression (Fig. 3, R = 0.225, P = 6.5 · 10−9).
This association, although highly significant, has a relatively
low R value. However, since we previously found a similar
association (R = 0.289, P = 6.2 · 10−3) in the Versteeg-88cohort [32], we felt strengthened in our argument that this
correlation is meaningful.
These results show that SPR mRNA expression is high-
est in all NB clinical groups with poor outcome: high age
at diagnosis, tumors with MYCN oncogene amplification,
and patients with high INSS tumor stage. Its expression
pattern therefore resembles that of ODC, and indeed we
found a tentative correlation between SPR and ODC ex-
pression. Together, these results prompted us to investi-
gate the specific targeting of SPR alone or together with
targeting of ODC as novel NB therapy.
The effect of Sulfasalazine (SSZ) treatment on NB cell
proliferation and survival
A recent study by Chidley et al. revealed that SSZ blocks
BH4 biosynthesis through inhibition of SPR [30]. To
examine the inhibitory effects of SSZ in NB cells, we
treated SK-N-Be(2)c, SK-N-SH, and LAN-5 cells with in-
creasing concentrations of SSZ (0–400 μM) and mea-
sured cell viability 48 h after treatment. As shown in
Fig. 4, SSZ decreased the cell viability of all three NB cell
lines in a dose-dependent manner. We did not observe
overt apoptosis (data not shown), suggesting that SSZ
inhibits cell proliferation of NB cells without cytotoxic
effects.
To investigate potential signaling molecules and path-
ways involved in SSZ-mediated cell death, we tested the
expression levels of several proteins that regulate cell
proliferation, including p27Kip1, retinoblastoma tumor
suppressor protein Rb, Akt/PKB, and p44/42 MAPK
(Erk1/2). Western blot analysis did not reveal any signifi-
cant protein expression differences between SSZ-treated
and untreated NB cells (data not shown), suggesting that
additional, alternative signaling pathways are activated
by SSZ.
Computational modeling and docking of SSZ into SPR
To examine if SPR binds SSZ, we performed computa-
tional docking simulations. SSZ is an amino-salicylate,
specifically 5-((4- (2- Pyridylsulfamoyl) phenyl)azo) sali-
cylic acid (Fig. 1). SSZ has one canonical conformer with
an MMFF94-minimized (Merck Molecular Force Field)
energy of 83.9 kcal/mol, which was used in the docking
simulations [33]. Under physiological conditions the mol-
ecule carries a negative charge which may have a role in
the interaction with the receptor.
The human SPR crystal structure is available in complex
with NADP+ in a hexameric assembly (unpublished data,
PDB: 1Z6Z). This biologically active, functional form of
SPR exists as a dimer and has 2-fold (180°) rotational sym-
metry. The SPR monomer is an alpha and beta (a/b) class
protein with a 3-layer (aba) sandwich architecture and
Rossmann fold topology, and it contains an NADP- bind-
ing Rossmann-like domain [34].
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Fig. 2 SPR mRNA expression correlation with NB clinical parameters. Differential expression of SPR mRNA expression in the Kocak-649 cohort upon separation
of patient samples into clinically important groups. (a) SPR expression is significantly higher in older than in younger patients (age at diagnosis ≥18 months
versus <18 months; P = 1.9 · 10−23), (b) SPR expression is significantly higher in patients with than in patients without tumor MYCN gene amplification
(P = 7.9 · 10−15), and (c) SPR expression is significantly higher in high than in low stage tumors (INSS stage 3 and 4 versus stage 1, 2, and 4S; various P< 0.05).
For all three parameters, SPR expression is highest in the poor outcome group. Statistical analysis was performed using the non-parametric
Kruskal-Wallis tests
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SPR monomer and the dimer. The docking computa-
tions were carried out on each binding mode by geo-
metric complementarity and semi-flexible docking to
allow for inherent receptor flexibility. From each
computation, the 50 lowest energy-docking positions
were saved for further analysis. The presumed SSZ-
binding sites were ranked by conservation score, spe-
cifically by the frequency of occurrence of a residue
in a contact surface. The contact surface was delim-
ited as an area consisting of the residues inside a
3.6 Å radius of the ligand.Based on the conservation scores of all the residues, we
identified the main binding location within the NADP-
binding Rossmann-like domain. A consensus of five bind-
ing regions constituted the receptor pocket comprising
residues Gly11, Ser13, Arg14, Phe16 (Region 1), Ala38,
Arg39 (Region 2), Asn97, Ala98, Gly99, Ser100 (Region 3),
Tyr167 (Region 4), and Leu198, Thr200, Met202 (Region 5).
Thus, the binding pocket appeared to contain 2 basic
polar residues, 5 neutral polar residues, and 7 neutral
non-polar residues. Due to the presence of 2 arginine resi-
dues, the site has a basic, positively charged character
which may be essential for SSZ binding. Most or all of
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Fig. 3 SPR expression correlation with ODC expression in NB. SPR and ODC mRNA expression correlation in the Kocak-649 NB cohort: visual representation
of SPR and ODC expression in all 649 NB tumor samples, ranked horizontally from left to right according to their SPR expression. SPR and ODC (2log)
expression values for each sample are visualized with red circles and black rectangles, respectively. The correlation between SPR and ODC expression is
r = 0.225, with a P value of 6.5 · 10−9 (2log Pearson). Symbols representing the clinical values of the tumor samples: age at diagnosis, MYCN amplification,
and INSS stage, are listed below the graph, together with their legend
Yco et al. BMC Cancer  (2015) 15:477 Page 5 of 11SSZ exists in a non-protonated, negatively charged state at
neutral pH, as the acidic pKa of carboxylic acid is 2.3 and
the pKa of the sulfonamide nitrogen is 6.5, i.e. less than
half-protonated at pH 7.0 [35].
The same residues listed above are involved in NADP+
binding, but the complete NADP+ binding site extends be-
yond these residues (Table 2). The monomeric or dimeric
state of SPR did not affect the location of the SSZ binding
site in the simulations, indicating that dimerization does0
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Fig. 4 Effect of Sulfasalazine (SSZ) on the viability of NB cells using
the MTS cell viability assay. NB cell lines SK-N-Be(2)c, SK-N-SH, and
LAN-5 were treated with increasing concentrations of SSZ for
48 hours. Dose-dependent inhibition of cell viability was observed.
Statistically significant differences between values obtained from
DMSO-treated control cells and SSZ-treated cells are indicated with
an asterisk (*P < 0.05) or solid triangle (▲P < 0.005). Data represent
the average of three independent experiments (n = 3); bars,
mean ± SEMnot directly block the access of ligand to the receptor.
Table 2 also lists the dimer interface residues. Indeed, the
interface residues do not share common elements with the
SSZ/NADPH+ binding pocket. Only Tyr167, which is part
of both ligand sites, is found in the vicinity of an interface
residue, i.e. Cys168.
Figure 5 shows the binding of SSZ to SPR monomer
and dimer, respectively. Both chains were found to sim-
ultaneously bind ligands in the dimer. While the SSZ site
is close to the N-terminus in the primary structure, it
appears near the middle of the protein in the 3D fold.
The binding pocket is not in very close contact with the
dimerization interface and only a few side chains project
into the joint neighborhood. The figure also shows the
NADP+ binding site of SPR in side-by-side comparison
and overlay mode with SSZ. The superimposition of the
ligands clearly illustrates that the two binding sites are es-
sentially the same. The geometric center of SSZ and
NADP+ is separated only by about 0.5 Å from each other
in the superimposed binding pockets. Thus, from Fig. 5
and Table 2 it appears that the binding site for SSZ coin-
cides with the region previously identified in NADP+
binding in the X-ray structure. As a consequence, this
could help elucidate the interaction between SSZ and SPR
in in vitro and in vivo studies.
Synergism of SSZ and DFMO combination treatment in
NB cells
To test whether the combined treatment with SSZ and
DFMO induces synergistic cell death in NB, we treated
Table 2 Amino acid residues at the binding sites of SPR-SSZ,
SPR-NADP+, and SPR-SPR complexes
SSZ NADP+ SPR Dimer
Pocket Pocket Interface
Gly11 Gly11 -
Ser13 Ser13 -
Arg14 Arg14 -
Gly15 -
Phe16 Phe16 -
Ala38 - -
Arg39 Arg39 -
- Asn40 -
- Ala65 -
- Asp66 -
- Leu67 -
- - Glu70
Asn97 Asn97 -
Ala98 - -
Gly99 - -
Ser100 - -
- - Gly107
- - Phe108
- - Val109
- - Asp110
- - Leu111
- - Ser114
- - Val117
- - Asn118
- - Trp121
- - Ala122
- Leu123 -
- - Thr126
- - Leu129
- - Ser133
- - Lys137
- Ile152 -
- Ser153 -
- - Pro160
- - Phe161
- - Lys162
- - Gly163
- - Ala165
Tyr167 Tyr167 -
- - Cys168
- - Ala169
- Lys171 -
Table 2 Amino acid residues at the binding sites of SPR-SSZ,
SPR-NADP+, and SPR-SPR complexes (Continued)
- - Ala173
- - Met176
- - Leu177
- - Val180
- - Leu181
- - Leu183
- - Glu184
- Pro195 -
- Gly196 -
- Pro197 -
Leu198 Leu198 -
Thr200 Thr200 -
Met202 Met202 -
- Gln203 -
Cutoff distance: 3.6 Angstrom
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tions of SSZ and DFMO. We used two common methods
to analyze drug-drug interactions, the isobologram and
the combination index (CI) analysis. For both combin-
ation analyses, we measured the SSZ and DFMO inter-
action at 50 % effect level. We first determined the single-
agent IC50 concentration for SSZ and DFMO in NB cell
lines SK-N-Be(2)c and LAN-5 (Fig. 6, a and b) using an
MTS cell viability assay after 48 h of treatment. SSZ ex-
hibited an IC50 value of 133.1 μM for SK-N-Be(2)c and
337.2 μM for LAN-5 cells. DFMO showed an IC50 value
of 4.07 mM for SK-N-Be(2)c and 5.79 mM for LAN-5
cells. Subsequently, we combined SSZ and DFMO at dif-
ferent concentrations based on each IC50 value to treat
the two NB cell lines, generated isobolograms, and calcu-
lated the CI values illustrating the observed synergy. As
shown in Fig. 6c and Table 3, SSZ and DFMO combina-
tions revealed slight synergism in SK-N-Be(2)c cells when
drug concentrations were below 29.64 μM and 1.80 mM,
respectively. Strikingly, SSZ and DFMO showed strong
synergism in LAN-5 cells when drug concentrations were
below 1.20 μM and 1.21 mM, respectively.
Discussion
SSZ is a salicylate-based anti-inflammatory drug; one of
the most important medicines used worldwide in basic
health care according to the WHO Model List of Essen-
tial Medicines (http://www.who.int/medicines/publica-
tions/essentialmedicines/en/). Its mode of action involves
the anti-inflammatory and immune-modulatory proper-
ties of its metabolic constituent, 5-aminosalicylic acid
[31, 36]. SSZ is most commonly used to treat bowel in-
flammation, diarrhea, rectal bleeding, and abdominal
ba
c d
e
Fig. 5 Binding of SSZ to SPR. (a) SPR dimer front view (C2 axis). Both chains bind SSZ independently. (b) SPR dimer in complex with NADP+. (c)
SPR monomer close-up front view of the SSZ binding pocket: (d) SPR monomer close-up front view of the NADP+ binding pocket. (e) Overlay
view of SSZ and NADP+ binding sites. The two binding sites overlap upon 3D alignment of the SPR protein chains. The amino acid residues
involved in SSZ and NADP binding are listed in Table 2. Color scheme for the molecular constituents: Protein chain ribbon - rainbow spectrum
from N-terminus (blue) to C-terminus (red); SSZ space fill – amber; NADP+ spacefill – cyan
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known about a potential therapeutic effect of SSZ in NB.
Molecular and computational studies presented in this
work and in [32] suggest that the SSZ target molecule
SPR may constitute a novel druggable protein in NB.
Both chains of the SPR homodimer were found to simul-
taneously bind ligands in the docking simulations and
the SSZ binding site was located at the NADP-binding
Rossmann fold. Thus, competition between SSZ and
NADP+ may modulate or inhibit the activity of SPR as
the two ligands do not have an equivalent enzymatic
role. In addition to occupying the same receptor pocket,
complex formation with SSZ could locally perturb the
dimerization interface. Binding region 4 includes the
aromatic residue Tyr 167 that is situated near the dimer
interface in a relatively apolar area and may affect the
thermodynamics of ligand and inhibitor binding as wellas the protein dimerization. It remains to be clarified in
further work whether the primary physiological role of
SSZ is competitive/non-competitive inhibition or per-
turbation of dimerization which would in turn disrupt
the functional biological unit in addition to the enzym-
atic changes.
Conclusions
The results of the NB cell experiments show that SSZ
has a detrimental effect on NB cells in in vitro culture
and shows synergy with DFMO treatment which is en-
couraging. The identification of the molecular pathways
that are activated in response to SSZ action will need
further studies. Considering the low toxicity of DFMO
and its current use in NB clinical trials [26–28], a com-
bination with the equally low toxic and clinically evalu-
ated SSZ appears a good lead for future clinical studies.
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Fig. 6 Isobologram analysis for SSZ and DFMO in NB. Isobolograms were prepared to determine synergisms between SSZ and DFMO. NB cell lines
SK-N-Be(2)c and LAN-5 were used to determine the inhibitory concentration at which 50 % of cells are dead (IC50) after 48 h of treatment with (a) SSZ
and (b) DFMO. (c) Isobologram analysis to determine the combined cytotoxicity of SSZ and DFMO using the IC50 values from (a and b). The IC50
value of SSZ and DFMO used in combination provides the connective points for the line of additive. Synergy, additivity, or antagonism is
indicated below, on, or above the line, respectively. The data present the average of three independent experiments in duplicate (n = 6);
points, mean ± SEM
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Mammalian cell culture and reagents
The human NB cell line SK-N-Be(2)c was obtained from
Dr. Giselle Sholler (Helen DeVos Children’s Hospital,
Grand Rapids, MI). The human NB cell line LAN-5 was
obtained from Dr. Randal Wada (John A. Burns School
of Medicine, University of Hawaii at Manoa, Honolulu,
HI). The human NB cell line SK-N-SH was purchased
from the American Type Culture Collection (Manassas,
VA). Cells were maintained in RPMI 1640 media (Med-
iatech Inc, Manassas, VA) containing 10 % heat-
inactivated fetal bovine serum (FBS) (Atlanta Biologicals,Inc, Lawrenceville, GA), penicillin (100 IU/mL), and
streptomycin (100 Ag/mL) (Mediatech). Sulfasalazine
(SSZ) (Santa Cruz Biotechnology, Inc, Dallas, TX) stock
solution was prepared at 250 mM concentration in di-
methyl sulfoxide (DMSO) (Electron Microscopy Sci-
ences, Hatfield, PA). DFMO was a kind gift of Dr.
Patrick Woster (Medical University of South Carolina,
Charleston, SC) and dissolved in water to make a stock
solution of 250 mM as previously reported [18, 19, 21].
SSZ and DFMO were diluted with culture medium be-
fore treating the cells. An equal concentration of DMSO
was used for control treatments.
Table 3 Combination treatment of SSZ and DFMO in SK-N-
Be(2)c and LAN-5 cells for 48 h
Concentration,
IC50 Equivalent
NB Cell
Line
SSZ DFMO Combination
Index at 50 %
Effect Level
Evaluation
at 50 %
Effect Level
SSZ IC50
(μM)
DFMO
(mM)
SK-N-
Be(2)c
0.408 0.425 0.834 slight
synergism
54.360 1.800
0.223 0.614 0.837 slight
synergism
29.640 2.600
0.314 0.803 1.117 moderate
antagonism
41.740 3.400
0.140 0.992 1.132 moderate
antagonism
18.700 4.200
0.415 1.181 1.595 antagonism 55.180 5.000
LAN-5 0.004 0.207 0.211 strong
synergism
1.207 1.200
0.173 0.311 0.484 synergism 58.250 1.800
0.015 0.466 0.482 synergism 5.152 2.700
0.439 0.691 1.130 moderate
antagonism
147.900 4.000
0.003 1.037 1.039 additive 0.893 6.000
Legend: The concentration in IC50 equivalent of SSZ was calculated by dividing
the IC50 of SSZ with DFMO combination from its corresponding single-agent IC50
value (IC50 of SSZ w/ DFMO comb/SSZ IC50). For DFMO, the concentration in IC50
equivalent was calculated by dividing its actual concentration used in the
combination treatment from its corresponding single-agent IC50 value (DFMO/
DFMO IC50). Combination index (CI) at 50 % effect level is calculated by adding
the IC50 equivalent concentration of SSZ and DFMO. CI >1.3 is antagonism; CI =
1.1-1.3 is moderate antagonism; CI = 0.9-1.1 is additive; CI = 0.8-0.9 is slight
synergism; CI = 0.6-0.8 is moderate synergism; CI = 0.4-0.6 is synergism; CI = 0.2-0.4 is
strong synergism. Synergism was detected at two different combinations of DFMO
and SSZ in SK-N-Be(2)c cells and three different combinations in LAN-5 cells (bold
italics). The data present the average of three independent experiments performed
in duplicate (n = 6)
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Prior to treatment, cells were cultured overnight in 96-well
microtiter plates (Greiner Bio-One Inc, Monroe, NC).
LAN-5, SK-N-Be(2)c, or SK-N-SH cells were seeded at con-
centrations of 1.5, 5.0, or 1.0 × 104 cells per well, respect-
ively. All NB cell lines were suspended in 90 μl of medium
per well. After overnight incubation, NB cells were treated
with increasing concentrations of SSZ (0–400 μM) or
DFMO (0–25 mM) for 48 h. An equal concentration of
DMSO was used as a control. Cell viability was measured
with the CellTiter 96 AQueous One Solution Cell Prolifera-
tion Assay (MTS Assay) (Promega BioSciences, San Luis
Obispo, CA) following the manufacturer’s protocol. Briefly,
20 μL of CellTiter 96 AQueous One Solution Reagent was
added to each well and incubated at 37 °C for 3 h. The
quantity of formazan product that is proportional to the
number of living cells in the culture was measured at
490 nm using the Synergy Mx Monochromator-Based
Multi-Mode Microplate Reader (BioTek Instruments,
Inc, Winooski, VT). Optical density (OD) readings werecalculated and evaluated using Excel spreadsheet soft-
ware (Microsoft, Redmund, WA).
Isobologram and combination index analyses
Isobologram and combination index (CI) analyses were
performed as previously described [37–40] with some
modifications. Isobologram analysis is a graphical presen-
tation of the interaction of two drugs at a chosen effect
level, such as 50 % effect level or IC50 equivalent concen-
tration. CI analysis is used to quantitatively measure the
interaction of two drugs at a chosen effect level. In this
study, the 50 % effect level was used for both analyses.
The IC50 values of SSZ and DFMO for SK-N-Be(2)c and
LAN-5 NB cell lines were calculated using the nonlinear
log inhibitor versus normalized response curve fit func-
tion from GraphPad Prism 6 software (La Jolla, CA).
Based on this single-agent IC50 determination, each NB
cell line was treated with a combination of SSZ and
DFMO at different concentrations. Seven different con-
centrations of SSZ ranging from 2.34 μM to 150 μM, and
5.47 μM to 350 μM were used to treat SK-N-Be(2)c and
LAN-5 cells, respectively. Five different concentrations of
DFMO ranging from 1.8 mM to 5.0 mM, and 1.2 mM to
6.0 mM were used to treat SK-N-Be(2)c and LAN-5, re-
spectively. The CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) was used to measure the
drug activity for each NB cell line. Excel spreadsheet soft-
ware and GraphPad Prism 6 software were used to plot
the isobologram and determined the CI for each NB cell
line combination treatment. The line of additivity on the
isobologram represents the 50 % effect level of each drug.
Protein–ligand docking
Atomic coordinates from X-ray crystal structures of hu-
man sepiapterin reductase (SPR; PDB:1Z6Z) were ob-
tained from the Protein Data Bank [41] and used for
molecular docking. The crystallographic assembly is a
homo 6-mer (A6) and the single repeating unit consists of
residues L(−)5 to K258. The protein chain is in complex
with NADP+. The quaternary structure of the biological
unit is a homo 2-mer (A2).
Sulfasalazine (Compound ID: 5384001/5359476) struc-
ture information was retrieved from the PubChem Sub-
stance and Compound Database [35]. Three-dimensional
coordinates were available for a stable conformer, energy
minimized by the MMFF94 force field [33].
Molecular docking was carried out to locate plausible
SSZ binding sites in SPR. The Global Range Molecular
Matching method (GRAMM) was employed on local
computers in high-resolution geometric docking modes
using both a long-distance-potentials approach [42] and
correlation techniques [43]. The GRAMM algorithm iden-
tifies the docking areas by computing the intermolecular
energy potential in protein–ligand complexes through a
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lecular positions and orientations. A low-resolution semi-
flexible mode was also used to account for conformational
flexibility [44, 45].
The docking simulations were run with SPR monomers
and dimers, each in complex with the energy–minimized
SSZ conformer. The first 50 binding locations of every run
were scored by the binding energy between the ligand and
the protein and by the presence or absence of amino acid
residues in the contact surfaces among the various pro-
tein–ligand pairs. The complexes with the lowest spatial
variations were chosen as the most plausible models. The
predicted binding sites were visualized with the ICM-
Browser (Molsoft, San Diego, CA). The ICM Molecular
Editor (Molsoft) was used for chemical structure drawing.
NB public mRNA expression dataset analysis
Human NB mRNA expression datasets in the public domain
were analyzed using R2: a genomics analysis and
visualization platform developed in the Department of
Oncogenomics at the Academic Medical Center – University
of Amsterdam (http://r2.amc.nl). Expression data (CEL
files) for the datasets were retrieved from the public Gene
Expression Omnibus (GEO) dataset on the NCBI website
(http://www.ncbi.nlm.nih.gov/geo/). All analysis of human
material and human data was in compliance with the
“Declaration of Helsinki for Medical Research involving
Human Subjects” (http://www.wma.net/en/30publica-
tions/10policies/b3/index.html). In addition, approval was
obtained from the “Medisch Ethische Commissie (MEC)
van het AMC (Amsterdam)”, the local research and ethics
committee. CEL data were analyzed as described in [46].
Briefly, gene transcript levels were determined from data
image files using GeneChip operating software (MAS5.0
and GCOS1.0, from Affymetrix). Samples were scaled by
setting the average intensity of the middle 96 % of all
probe-set signals to a fixed value of 100 for every sample in
the dataset, allowing comparisons between micro-arrays.
The TranscriptView genomic analysis and visualization tool
within R2 was used to check if probe-sets had an anti-sense
position in an exon of the gene (http://r2.amc.nl > genome
browser). The probe-sets selected for SPR (Affymetrix
203458_at and Illumina 1705849) and ODC1 (Affymetrix
200790_at and Illumina 1748591) meet these criteria. All
expression values and other details for the datasets used
can be obtained through their GSE number from the NCBI
GEO website.
Statistical analysis
SPR mRNA expression and correlation with important
NB clinical parameters were determined using the non-
parametric Kruskal-Wallis test; correlation with ODC
mRNA expression was calculated with a 2log Pearson
test. The significance of a correlation is determined byt = R/sqrt((1-r^2)/(n-2)), where R is the correlation value
and n is the number of samples. Distribution measure is
approximately as t with n-2° of freedom. For all tests, P
< 0.05 was considered statistically significant. The statis-
tical significance of SSZ treatments in cell viability ex-
periments was determined by Microsoft Excel’s Student’s
paired t-Test, with one-tailed distributions.
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